In addition, candidate chemicals from our screening showed synergistic effect with 3rd‐generation inhibitor, osimertinib in some EGFR‐mutated NSCLC cells (Fig. S5), suggesting that our screens are probably applicable for enhancing the effect of 3rd‐generation inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.